Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity | Zendy

Charles Guénancia | Zendy; Olivier Hachet | Zendy; Mona E. Aboutabl | Zendy; Na Li | Zendy; Eve Rigal | Zendy; Yves Cottin | Zendy; Luc Rochette | Zendy; Catherine Vergely | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity

Author(s) -

Charles Guénancia,

Olivier Hachet,

Mona E. Aboutabl,

Na Li,

Eve Rigal,

Yves Cottin,

Luc Rochette,

Catherine Vergely

Publication year - 2016

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-016-2995-9

Subject(s) - cardiotoxicity , overweight , medicine , trastuzumab , doxorubicin , ejection fraction , endocrinology , saline , pharmacology , chemotherapy , cancer , heart failure , breast cancer , obesity

Trastuzumab (TRZ) is believed to potentiate doxorubicin (DOX) cardiotoxicity, resulting in left ventricular dysfunction. There is some evidence that overweight could influence anticancer drug-induced cardiotoxicity, though no study has evaluated the impact of moderate overweight, induced by postnatal nutritional programming, on the cardiotoxic effects of DOX alone or in combination with TRZ.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research